Loading clinical trials...
Loading clinical trials...
A SINGLE-DOSE, OPEN LABEL, RANDOMIZED, 3-WAY CROSSOVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 100/6 pMDI (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg) WITH OR WITHOUT SPACER DEVICE VERSUS THE FREE COMBINATION OF LICENSED BECLOMETHASONE pMDI AND FORMOTEROL pMDI IN ASTHMATIC ADOLESCENT PATIENTS AND ONE OPEN ARM FOR ADULT PATIENTS AS CONTROL GROUP TREATED WITH CHF 1535 100/6 pMDI.
Conditions
Interventions
Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).
+2 more
Locations
1
Poland
Uniwersytecki Szpital Kliniczny nr 1
Lodz, Poland
Start Date
February 1, 2012
Primary Completion Date
October 1, 2012
Completion Date
October 1, 2012
Last Updated
July 31, 2020
NCT02327897
NCT07486401
NCT07219173
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions